TOPLUM VE HASTANE KAYNAKLI İNFEKSİYONLARDAN İZOLE ...
TOPLUM VE HASTANE KAYNAKLI İNFEKSİYONLARDAN İZOLE ...
TOPLUM VE HASTANE KAYNAKLI İNFEKSİYONLARDAN İZOLE ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
24-Nathwani D.Tigecycline: Clinical evidence and formulary positioning.İnt J Antimicrob<br />
Agents.2005;25:185-92.<br />
25-- http:// journals.prous.com/journals/dof/20093402/html/df340127/images/str18.gif<br />
26‐ Zhane l GG, Karlowsky JA,Rubinstein E,Hoban D.Tigecycline:A new Glyccyclcline<br />
antibiotic.Expert Rev Anti İnfect Ther. 2006;4:9-25<br />
27-ZhanelGG, Homenuik K,Nichol K, et all.The Glyccyclclines:A comperativereview with<br />
the tetracyclines.Drugs 2004;64:63-88<br />
28- Sonia Borbone, Agnese Lupo, Maria Lina Mezzatesta, Floriana Campanile, Maria<br />
Santagati,Stefania Stefani. Evaluation of the in vitro activity of tigecycline against<br />
multirezistant Gram-pozitive cocci containing tetracycline rezistance determinants.<br />
İnternational Journal of Antimicrobial Agents 31(2008)209-215<br />
29- Thomas R. Fritsche, Helio S. Sader, Matthew G. Stilwel, Michael J. Dowzicky,<br />
Ronald N. Jones.Potency and spectrum of tigecycline tested against an international collection<br />
of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagnostic<br />
Microbiology & Infectious Disease, 2005<br />
30- Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a<br />
novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).<br />
Antimicrob Agents Chemother1999; 43: 738–44.<br />
31- Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936tested<br />
against antibiotic-resistant Gram-positive blood stream infection isolatesandstrains<br />
producingextended-spectrumb-lactamases.Diagn Microbiol Infect Dis 2001; 40: 173–7.<br />
32.-Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline,<br />
GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis<br />
2000; 36: 19–36.<br />
33- Postier RG, Green SL, Klein SR et al. Tigecycline 200 Study Group. Results of a<br />
multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for<br />
complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:<br />
704–14.<br />
34- Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline<br />
(GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents<br />
Chemother 2003; 47: 400–4.<br />
62
Change language